Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.62 |
| ▸ | CDK7 | P50613 | 16/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.62 |
| ▸ | CCNH | P51946 | 14/20 | 0.62 |
| ▸ | CDK9 | P50750 | 9/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.62 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 13/20 | 0.59 |
| ▸ | CDK4 | P11802 | 12/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.59 |
| ▸ | CCND1 | P24385 | 10/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.59 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15118114 | 0.91 | CDK2 (0.63) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL15117963 | 0.91 | CDK2 (0.75) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL15118208 | 0.91 | CDK2 (0.62) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL15118181 | 0.91 | CDK2 (0.62) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL15117612 | 0.91 | CDK2 (0.74) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL786564 | 0.90 | CDK2 (0.65) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL15118022 | 0.89 | CDK2 (0.60) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL785935 | 0.87 | CDK2 (0.60) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL786323 | 0.87 | CDK2 (0.58) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL786849 | 0.86 | CDK2 (0.66) | CDK2CDK7CCNE1CCNHCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438068-B1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2017-03-01 | — | — | EP | claimed |
| US-8492391-B2 | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2013-07-23 | — | — | US | claimed |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2012-03-22 | — | — | US | claimed |
| EP-2438068-B1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2017-03-01 | — | — | EP | disclosed |
| US-8492391-B2 | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2013-07-23 | — | — | US | disclosed |
| EP-2438068-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2012-04-11 | — | — | EP | disclosed |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2012-03-22 | — | — | US | disclosed |
| WO-2010139289-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | CDK6, CCNI, CDK2 | CDK2 3/4885CDK7 8/4885CCNE1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.